Cizzle Biotechnology (LSE: CIZ) is developing a simple blood test to detect lung cancer early, when treatment is most effective.
Shareholder Information
Cizzle Biotechnology Holdings plc‘s shares are traded on Main Market of the London Stock Exchange.
Significant Shareholders
As at 08 April 2025, as far as the Directors are aware, the following shareholders have a significant interest in the issued share capital of the Company.
Name
Number of Ordinary Shares
% of Issued Share Capital
Hargreaves Lansdown (Nominees) Limited
44,809,977
11.30
Yorkshire Cancer Research
32,382,330
8.17
Interactive Investor Services Nominees Limited
31,333,630
7.90
Hargreaves Lansdown (Nominees) Limited
29,870,003
7.54
Hargreaves Landsown (Nominees) Limited
28,109,647
7.809
Barclays Direct Investing Nominees Limited
20,322,951
5.13
Interactive Investor Services Nominees Limited
19,460,025
4.91
HSDL Nominees Ltd
17,226,581
4.35
Professor Dawn Coverley*
17,048,137
4.30
HSBC Global Custody Nominee (UK) Limited
14,718,227
3.71
* the shareholding of Professor Dawn Coverley includes shares held by Dawn’s husband, Dr Juston Ainscough.